Presence of Helicobacter Species in Gastric Mucosa of Human Patients and Outcome of Helicobacter Eradication Treatment

Data de publicação:

Autores da FMUP

  • Hugo Miguel Teixeira Ferraz Santos Sousa

    Autor

  • Celso Albuquerque Reis

    Autor

  • Maria De Fátima Machado Henriques Carneiro

    Autor

Participantes de fora da FMUP

  • Matos, R
  • Taillieu, E
  • De Bruyckere, S
  • De Witte, C
  • Rema, A
  • Nogueiro, J
  • Haesebrouck, F
  • Amorim, I
  • Gaertner, F

Unidades de investigação

Abstract

The genus Helicobacter is composed of bacteria that colonize both the human and animal gastrointestinal tract. Helicobacter pylori infects half of the world's population, causing various disorders, such as gastritis, duodenitis and gastric cancer. Additionally, non-Helicobacter pylori Helicobacter species (NHPH) are commonly found in the stomach of pigs, dogs and cats. Most of these species have zoonotic potential and prevalence rates of 0.2-6.0%, and have been described in human patients suffering from gastric disorders undergoing a gastric biopsy. The aim of this study was to determine the occurrence of Helicobacter spp. in the stomach of patients with gastric cancer (n = 17) and obese (n = 63) patients. Furthermore, the outcome of the Helicobacter eradication treatment and the current infection status was evaluated. Overall, based on the genus-specific PCR followed by sequencing, DNA from Helicobacter spp. was detected in 46.3% of the patients, including single infections with H. pylori in 43.8% of the patients and mixed infections with H. pylori and canine- or feline-associated H. felis in 2.5%. About 32.5% of the patients had been subjected to previous Helicobacter eradication therapy and the triple standard therapy was the most frequent scheme (42.3%). In 48.0% of the patients who received eradication treatment, bacteria were still detected, including one mixed infection. In 23.1% of the patients who reported that a subsequent test had been performed to confirm the elimination of the bacteria, Helicobacter were still detected. In conclusion, although in a smaller percentage, NHPH may also be present in the human stomach. Thus, specific NHPH screening should be included in the diagnostic routine. The continued presence of H. pylori in the stomach of patients recently subjected to eradication schemes raises questions about the efficacy of the current Helicobacter treatments.

Dados da publicação

ISSN/ISSNe:
2075-4426, 2075-4426

Journal of Personalized Medicine  Multidisciplinary Digital Publishing Institute (MDPI)

Tipo:
Article
Páginas:
181-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 6

Citações Recebidas na Scopus: 4

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Helicobacter; NHPH; human stomach; gastric disease; eradication treatment

Financiamento

Proyectos asociados

Impact of Platelet-Lymphocyte Ratio (PLR) in the prognosis of Gastric Cancer patients

Investigador Principal: Hugo Miguel Teixeira Ferraz Santos Sousa

Estudo Clínico Académico (PLR) . 2020

Impact of serum albumin concentration and neutrophil-lymphocyte ratio score on gastric cancer prognosis

Investigador Principal: Hugo Miguel Teixeira Ferraz Santos Sousa

Estudo Clínico Académico (gastric cancer prognosis . 2020

Nutritional deficiencies in bariatric surgery patients: a comparison between Roux-en-Y Gastric Bypass and Sleeve Gastrectomy

Investigador Principal: Hugo Miguel Teixeira Ferraz Santos Sousa

Estudo Clínico Académico . 2021

Expression of Thomsen-Friedenreich Antigen in colorectal cancer and association with microsatellite instability

Investigador Principal: Celso Albuquerque Reis

Estudo Clínico Académico . 2021

The role of hepatocyte apoptosis markers in predicting the histological and serological activity in steatohepatitis

Investigador Principal: Maria de Fátima Machado Henriques Carneiro

Estudo Clínico Académico . 2021

Roux-en-Y Gastric Bypass and Sleeve Gastrectomy as Revisional Bariatric Procedures after Adjustable Gastric Banding: a retrospective cohort study

Investigador Principal: Hugo Miguel Teixeira Ferraz Santos Sousa

Estudo Clínico Académico (Gastric Bypass) . 2021

High-Sensitivity modified Glasgow Prognostic Score (HS-mGPS) as a predictor of overall survival in gastric cancer patients submitted to curative-intent surgery

Investigador Principal: Hugo Miguel Teixeira Ferraz Santos Sousa

Estudo Clínico Académico . 2020

Gastric Cancer Morphological, Immunophenotypic and molecular heterogeneity

Investigador Principal: Maria de Fátima Machado Henriques Carneiro

Estudo Clínico Académico . 2020

Citar a publicação

Partilhar a publicação